| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Pulmonary Division, University Hospital, Basel, Switzerland, 2 Atlantic Asthma & Allergy Center Inc., Baltimore, USA, 3 Creighton University School of Medicine, Omaha, USA, 4 Johannes-Gutenberg-Universitat III, Medizinische Klinik und Poliklinik, Mainz, Germany, 5 City Park Medical Centre, Capetown, South Africa, 6 Novartis Horsham Research Centre, Horsham, England, 7 Novartis Pharmaceuticals Corporation, East Hanover, USA
CORRESPONDENCE: M. Solèr, Pulmonary Division, University Hospital, Petersgraben 4, CH-4031, Basel, Switzerland. Fax: 41 612654587
Keywords: airway inflammation, allergic asthma, anti-allergic drugs, anti-immunoglobulin-E antibody, immunoglobulin-E, omalizumab
Received: October 26, 2000
Accepted April 5, 2001
This study was supported by Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA, USA.
The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma.
After a run-in period, 546 allergic asthmatics (aged 12–76 yrs), symptomatic despite inhaled corticosteroids (500–1,200 µg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable.
Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p<0.001). During the steroid-reduction phase, there were 52% fewer exacerbations in the omalizumab group versus the placebo group (p<0.001) despite the greater reduction of the beclomethasone dosage on omalizumab (p<0.001). Treatment with omalizumab was well tolerated. The incidence of adverse events was similar in both groups.
These results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in corticosteroid requirement.
This article has been cited by other articles:
|
|
 |
|
  D. M. LANG New asthma guidelines emphasize control, regular monitoring Cleveland Clinic Journal of Medicine, September 1, 2008; 75(9): 641 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bousquet, U. Wahn, E. O. Meltzer, H. Fox, S. Hedgecock, K. Thomas, and A. Fowler-Taylor Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases Eur. Respir. Rev., April 1, 2008; 17(107): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Hanania Targeting Airway Inflammation in Asthma: Current and Future Therapies Chest, April 1, 2008; 133(4): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. von Garnier, M. E. Wikstrom, G. Zosky, D. J. Turner, P. D. Sly, M. Smith, J. A. Thomas, S. R. Judd, D. H. Strickland, P. G. Holt, et al. Allergic Airways Disease Develops after an Increase in Allergen Capture and Processing in the Airway Mucosa J. Immunol., November 1, 2007; 179(9): 5748 - 5759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hamelmann The rationale for treating allergic asthma with anti-IgE Eur. Respir. Rev., September 1, 2007; 16(104): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Eur. Respir. Rev., September 1, 2007; 16(104): 73 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Holgate How to evaluate a patient's response to anti-IgE Eur. Respir. Rev., September 1, 2007; 16(104): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hendeles and C. A Sorkness Anti-Immunoglobulin E Therapy with Omalizumab for Asthma Ann. Pharmacother., September 1, 2007; 41(9): 1397 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gomez, S. Jogie-Brahim, M. Shima, and L. B. Schwartz Omalizumab Reverses the Phenotypic and Functional Effects of IgE-Enhanced Fc{epsilon}RI on Human Skin Mast Cells J. Immunol., July 15, 2007; 179(2): 1353 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wechsler, J.-A. O. Shepard, and E. J. Mark Case 15-2007 -- A 20-Year-Old Woman with Asthma and Cardiorespiratory Arrest N. Engl. J. Med., May 17, 2007; 356(20): 2083 - 2091. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Erin, O. M. Kon, P. J. Barnes, and T. T. Hansel Study of Infliximab Treatment in Asthma Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 196a - 197. [Full Text] [PDF]
|
|
|
|
|
|
M. Kraft, C. B. Cairns, M. C. Ellison, J. Pak, C. Irvin, and S. Wenzel Improvements in Distal Lung Function Correlate With Asthma Symptoms After Treatment With Oral Montelukast Chest, December 1, 2006; 130(6): 1726 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Strunk and G. R. Bloomberg Omalizumab for asthma. N. Engl. J. Med., June 22, 2006; 354(25): 2689 - 2695. [Full Text] [PDF]
|
|
|
|
 |
|
 W D Carroll, W Lenney, F Child, R C Strange, P W Jones, M K Whyte, R A Primhak, and A A Fryer Asthma severity and atopy: how clear is the relationship? Arch. Dis. Child., May 1, 2006; 91(5): 405 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bosco, K. L. McKenna, C. J. Devitt, M. J. Firth, P. D. Sly, and P. G. Holt Identification of novel th2-associated genes in T memory responses to allergens. J. Immunol., April 15, 2006; 176(8): 4766 - 4777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marcus Incorporating Anti-IgE (Omalizumab) Therapy Into Pulmonary Medicine Practice: Practice Management Implications. Chest, February 1, 2006; 129(2): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Immunotherapy Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S46 - S50. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Littner, F. W. Leung, E. D. Ballard II, B. Huang, N. K. Samra, and on behalf of the Lansoprazole Asthma Study Group Effects of 24 Weeks of Lansoprazole Therapy on Asthma Symptoms, Exacerbations, Quality of Life, and Pulmonary Function in Adult Asthmatic Patients With Acid Reflux Symptoms Chest, September 1, 2005; 128(3): 1128 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Djukanovic, S. J. Wilson, M. Kraft, N. N. Jarjour, M. Steel, K. F. Chung, W. Bao, A. Fowler-Taylor, J. Matthews, W. W. Busse, et al. Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 583 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Sin, J. Man, H. Sharpe, W. Q. Gan, and S. F. P. Man Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis JAMA, July 21, 2004; 292(3): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A Davis Omalizumab: A Novel Therapy for Allergic Asthma Ann. Pharmacother., July 1, 2004; 38(7): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bousquet, S. Wenzel, S. Holgate, W. Lumry, P. Freeman, and H. Fox Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma Chest, April 1, 2004; 125(4): 1378 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Silkoff, F. A. Romero, N. Gupta, R. G. Townley, and H. Milgrom Exhaled Nitric Oxide in Children With Asthma Receiving Xolair (Omalizumab), a Monoclonal Anti-Immunoglobulin E Antibody Pediatrics, April 1, 2004; 113(4): e308 - e312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hanf, O. Noga, A. O'Connor, and G. Kunkel Omalizumab inhibits allergen challenge-induced nasal response Eur. Respir. J., March 1, 2004; 23(3): 414 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Boushey New and Exploratory Therapies for Asthma Chest, March 1, 2003; 123(2007): 439S - 445S. [Full Text] [PDF]
|
|
|
|
|
|
H Milgrom Is there a role for treatment of asthma with omalizumab? Arch. Dis. Child., January 1, 2003; 88(1): 71 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl, G. Hanf, M. Soler, G. Bensch, J. Wolfe, F. Everhard, K. Champain, H. Fox, and J. Thirlwell The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Eur. Respir. J., November 1, 2002; 20(5): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Phipatanakul The Anti-IgE Antibody Omalizumab Reduces Exacerbations and Steroid Requirement in Sallergic Asthmatics Pediatrics, August 1, 2002; 110(2): 464 - 465. [Full Text] [PDF]
|
|
|
|
 |
|
 C M Richardson, A R L Medford, and R H Green British Thoracic Society Winter Meeting 2001 Thorax, April 1, 2002; 57(4): 286 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mazer Omalizumab reduced inhaled corticosteroid use and exacerbations in childhood allergic asthma Evid. Based Med., January 1, 2002; 7(1): 12 - 12. [Full Text] [PDF]
|
|
|
|
|
|
P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids Eur. Respir. J., January 1, 2002; 19(1): 182 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Casale, J. Condemi, C. LaForce, A. Nayak, M. Rowe, M. Watrous, M. McAlary, A. Fowler-Taylor, A. Racine, N. Gupta, et al. Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial JAMA, December 19, 2001; 286(23): 2956 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chanez Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations Eur. Respir. J., August 1, 2001; 18(2): 249 - 250. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
